The purpose of the study is to see if galantamine HBr (Razadyne) is safe and can help treat
problems with thinking and memory caused by electroconvulsive therapy (ECT).
- Criteria to enter the study include males and females between the ages of 18-90
(females must be post menopausal) and a DSM-IV diagnosis of Major Depressive
Disorder, Major Depressive Disorder with psychotic features, Bipolar Disorder,
depressed type, or Schizoaffective Disorder, depressed type (19).
- DSM-IV diagnoses of dementia and its subtypes
- Substance use disorder (active use within the last 6 months)
- Organic mental disorders; seizure disorder
- Unstable physical disorder or physical disorder judged to significantly affect the
central nervous system function
- A heart rate of <60
- A systolic blood pressure < 90
- Heart block
- Pre-existing sick-sinus
- Chronic treatment with beta blockers
- Any cardiac arrythmia
- Coronary artery disease
- Liver and renal function impairment
- Urge incontinence, colitis Crohn's disease, GI motility disorders, asthma and COPD
- Treatment with anti-cholinergic and cholinomimetic medications; and
- Female patients who are pregnant.
- Additionally, women subjects must be postmenopausal, surgically sterile, or using
prescription oral contraceptives (e.g. estrogen-progestin combinations) ,
contraceptive implants (e.g. NorplantTM, DepoProveraTM ), or transdermally delivered
contraceptives (Ortho EvraTM) before entry and throughout the study; and have a
negative serum b-HCG pregnancy test at screening.
Note: Abstinence and the use of double barrier contraceptive methods are not acceptable in